BNP 1350

Known as: BNP-1350, BNP1350, DB 172 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2016
01220002016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The poor prognosis of malignant glioma patients highlights the need to develop low toxicity, tumor specific agents with the… (More)
Is this relevant?
2009
2009
Organic anion-transporting polypeptides (OATPs) are important uptake transporters that can have a profound impact on the systemic… (More)
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2005
2005
PURPOSE A phase II trial of the novel camptothecin karenitecin (BNP1350) was conducted to determine its efficacy and tolerability… (More)
  • table 2
  • table 3
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2004
2004
BNP1350 (7-[(2-trimethylsilyl)ethyl]-20(S)-camptothecin, karenitecin), a highly lipophilic camptothecin, a high percentage of… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2002
2002
A novel karenitecin, BNP1350, is a topoisomerase I-targeting anticancer agent with significant antitumor activity in vitro and in… (More)
Is this relevant?
2002
2002
The novel camptothecin derivative BNP1350 (7-[2-trimethylsilyl)ethyl]-20(S)-camptothecin), also known as Karenitecin, has been… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
This study was aimed at characterizing the role of BCRP/MXR/ABCP (BCRP) in resistance of the human ovarian tumor cell lines T8… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2001
2001
Promotion of apoptosis may potentiate the sensitivity of tumor cells to chemotherapeutic agents, thus improving the efficacy of… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 6
Is this relevant?
2000
2000
BNP1350, 7-[(2-trimethylsilyl)ethyl]-20(S)-camptothecin, is a novel semi-synthetic, highly lipophilic, silicon-containing… (More)
Is this relevant?
2000
2000
Cellular topoisomerase I is an important target in cancer chemotherapy. A novel karenitecin, BNP1350, is a topoisomerase I… (More)
  • figure 2
  • figure 3
  • figure 5
  • figure 6
  • figure 7
Is this relevant?